| Year |
Citation |
Score |
| 2020 |
Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107 |
0.321 |
|
| 2019 |
Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, Simuni T, Coffey CS, Galasko D, Mollenhauer B, Arnedo V, Daegele N, Frasier M, Tanner C, Kieburtz K, Marek K, et al. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease. PMID 31450510 DOI: 10.3233/Jpd-181518 |
0.308 |
|
| 2018 |
Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology. 5: 1460-1477. PMID 30564614 DOI: 10.1002/Acn3.644 |
0.314 |
|
| 2018 |
Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, et al. Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29572948 DOI: 10.1002/Mds.27361 |
0.3 |
|
| 2017 |
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. PMID 29030452 DOI: 10.1212/Wnl.0000000000004609 |
0.303 |
|
| 2017 |
Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, et al. A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28734051 DOI: 10.1002/Mds.27090 |
0.304 |
|
| 2017 |
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. Plos One. 12: e0175674. PMID 28520803 DOI: 10.1371/Journal.Pone.0175674 |
0.305 |
|
| 2016 |
Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathologica. PMID 27021906 DOI: 10.1007/S00401-016-1552-2 |
0.3 |
|
| 2014 |
Yeatts SD, Martin RH, Coffey CS, Lyden PD, Foster LD, Woolson RF, Broderick JP, Di Tullio MR, Jungreis CA, Palesch YY. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke; a Journal of Cerebral Circulation. 45: 1408-14. PMID 24699059 DOI: 10.1161/Strokeaha.113.003925 |
0.302 |
|
| 2011 |
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/J.Pneurobio.2011.09.005 |
0.308 |
|
| 2007 |
Howard G, McClure LA, Krakauer JW, Coffey CS. Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials. Current Opinion in Neurology. 20: 71-7. PMID 17215692 DOI: 10.1097/Wco.0B013E328013Dbc8 |
0.323 |
|
| Show low-probability matches. |